Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MetLife, Inc. (NYSE: MET) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-supported tools to help interpret them. MetLife is a global financial services company offering insurance, annuities, employee benefits and asset management, with operations in more than 40 markets and leading positions in the United States, Asia, Latin America, Europe and the Middle East.
Investors can review current reports on Form 8-K, where MetLife discloses material events such as earnings announcements, segment reorganizations, acquisitions, reinsurance transactions and dividend declarations. Recent 8-K filings describe the designation of MetLife Investment Management (MIM) as a reportable segment, the reclassification of MetLife Holdings, the acquisition of PineBridge Investments, and a variable annuity reinsurance transaction with Talcott Resolution Life Insurance Company. Other 8-Ks address preliminary variable investment income information, preferred stock matters, and the company’s response to an unsolicited mini-tender offer.
Through this page, users can also locate quarterly and annual reporting materials referenced in MetLife’s filings, such as earnings releases, Quarterly Financial Supplements, total assets under management fact sheets and historical results supplements. These documents provide detail on segment performance across Group Benefits, Retirement and Income Solutions, regional insurance operations and MetLife Investment Management, as well as information on variable investment income and capital management.
Stock Titan’s platform enhances these filings with AI-powered summaries that explain key terms, highlight important changes and help clarify how specific disclosures may relate to MetLife’s broader business. Users can quickly identify items related to dividends, capital structure, segment changes, asset management acquisitions and risk transfer transactions without reading every line of each filing.
MetLife director Diana McKenzie reported a small compensation-related share increase. She acquired 189 shares of MetLife common stock on an imputed basis at $70.60 per share through reinvested dividends in the MetLife Deferred Compensation Plan for Non-Management Directors. Following this grant, she directly holds 23,751 common shares, reflecting routine deferred compensation rather than an open-market purchase.
MetLife Inc. director Jeh C. Johnson reported an acquisition of 65 shares of MetLife common stock on March 10, 2026 at an imputed price of $70.60 per share. The filing states this resulted from imputed reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors.
After this award, Johnson directly holds 8,129 MetLife common shares. The footnote explains that the deferred shares represent MetLife common stock that has become payable, but whose receipt Johnson has chosen to defer.
MetLife director Robert Glenn Hubbard received 771 shares of Common Stock at $70.60 per share as a grant under the MetLife Deferred Compensation Plan for Non-Management Directors.
The footnote explains this was an imputed reinvestment of dividends on deferred shares. After this compensation-related acquisition, he directly holds 104,630 MetLife shares.
MetLife Inc director Laura J. Hay acquired 40 shares of common stock on March 10, 2026 at $70.60 per share. The filing describes this as a grant or award, specifically an imputed reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors.
Following this transaction, Hay directly holds 4,971 shares of MetLife common stock. The deferred shares have become payable, but she has chosen to defer actual receipt of the shares.
MetLife Inc. director William E. Kennard acquired additional common stock through a compensation-related award. On 2026-03-10, he received 365 shares of MetLife common stock at $70.60 per share, reflecting imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
After this award, Kennard directly holds 45,780 MetLife common shares. He also has an additional 10 shares held indirectly through the MetLife Policyholder Trust, which was established to hold stock allocated to eligible policyholders. These transactions are non-open-market and arise from director compensation and trust holdings rather than discretionary buying or selling.
MetLife director Christian Stephane Mumenthaler acquired 17 shares of common stock as a grant under the MetLife Deferred Compensation Plan for Non-Management Directors. The award, recorded at a reference price of $70.60 per share, brings his directly held MetLife shares to 2,125.
MetLife Inc director Carla A. Harris reported acquiring 43 shares of common stock on March 10, 2026 at $70.60 per share. The filing explains this was an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
After this award, Harris directly holds 9,764 MetLife common shares. The transaction reflects compensation-related dividend reinvestment rather than an open-market stock purchase.
MetLife, Inc. filed a report confirming a previously announced first quarter 2026 dividend on its floating rate non-cumulative preferred stock, Series A. The dividend is $0.31501229 per share on shares with a $25 liquidation preference.
The company stated that the dividend will be payable on March 16, 2026, to shareholders of record as of Friday, February 27, 2026, because the normal record date of March 1, 2026 falls on a Sunday. The New York Stock Exchange had not yet set an ex-dividend date for the Series A preferred stock at the time of the announcement and is expected to set it following this confirmatory announcement.
MetLife Inc. executive John D. McCallion reported a tax-related share disposition. On March 2, 2026, 6,985 shares of MetLife common stock were withheld at $73.24 per share to cover taxes on vested restricted stock units. After this non-market transaction, he directly owned 275,194 shares.
MetLife Inc executive Shurawl Sibblies, EVP & Chief HR Officer, reported a tax-withholding disposition related to restricted stock units. On March 2, 2026, 220 shares of common stock were withheld at $73.24 per share for taxes, leaving her with 28,036 directly owned shares.